On January 13, 2026, Ms. Feng Lan, Vice President of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), together with Professor Li Wenbin, Chairman of PhIRDA Clinical Research on Neuro-Drugs Specialty Committee and Director of Cancer Center, Beijing Tiantan Hospital, Capital Medical University, met with Dr. Rawiwan Charoensub, Director, Medicinal Plants Innovation Center and School of Integrative Medicine, Mae Fah Luang University, and Professor Veron Ramsuran, Research Professor, Nelson Mandela School of Medicine, University of KwaZulu-Natal. The discussions focused on strengthening international multiregional clinical trials collaboration with China and facilitating the entry of Chinese innovative drugs into the Thai and South African markets.

Ms. Feng Lan extended a warm welcome to the academic delegations from both countries. She noted that PhIRDA has long been committed to advancing research on policies and industrial ecosystems that support domestic pharmaceutical innovation, as well as assisting Chinese innovative pharmaceutical companies in expanding into global markets. She expressed the hope that this exchange would further promote multiregional clinical trials of Chinese innovative drugs and accelerate the global accessibility of China-originated innovative drugs, benefiting patients in Belt and Road countries and beyond.

Professor Veron Ramsuran and Professor Rawiwan Charoensub respectively introduced the key research achievements of their teams, highlighted their core strengths in clinical trial platform development, and expressed strong interest in deepening cooperation with Chinese pharmaceutical companies. They stated their expectation to participate in multiregional clinical trials of Chinese innovative drugs, thereby facilitating the local adoption of advanced therapies and jointly improving drug accessibility for patients in emerging markets.

Meeting

The meeting focused on the advancement pathway for multiregional clinical trials of QH104A Injection, developed by UNICET - a globally first-in-class allogeneic, off-the-shelf CAR-γδT cell therapy targeting B7-H3. Professor Li Wenbin introduced that the product has received FDA approval to initiate clinical trials and has been granted Orphan Drug Designation in the United States. It is currently the world’s only allogeneic CAR-T candidate in clinical development for malignant glioma. All parties agreed on the importance of jointly advancing the clinical research deployment of this product in countries including Thailand and South Africa, setting a demonstrative example for Chinese innovative drugs to enter the global market. Attendees include Dr. Research Clinician, Nelson Mandela School of Medicine, University of KwaZulu-Natal; Mr. Yoo Seung Kim, CEO of Macro HRD SG Pte. Ltd., Singapore; Ms. Lu Xiaoti, Deputy Secretary-General of PhIRDA; Ms. Ruan Xinxin, Director of the International Department of PhIRDA; Ms. Tong Lianghui, Deputy Director of the Project Cooperation Department of PhIRDA; and Mr. Ma Weiwei, Co-founder and Chief Technology Officer of UNICET Co., Ltd.

Group Photo